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Abstract The novel superantigen designated as Yersinia 
pseudotuberculosis-deriyed mitogen typeB (YPMb) was purified 
from the cell lysate of Y. pseudotuberculosis 0:6 strain (R-104). 
Proliferative response of human peripheral blood mononuclear 
cells to the purified YPMb was detectable at a concentration of 
as low as 1 pg/ml, that is comparable to the previously 
documented YPM (YPMa). The VP repertoire specificity (3, 9, 
13.1 and 13.2) of YPMb was also the same as that of YPMa. A 
gene (ypmB) encoding YPMb was cloned and its nucleotide 
sequence was determined. The open reading frame (ORF 453 bp) 
of the ypmB encodes a protein with 150 amino acid residues, 
though the precursor protein of YPMa consists of 151 amino acid 
residues. There is a nucleotide sequence homology of 88.9% 
between ypmB and ypmA. The low homology in the downstream 
of the structural gene between ypmB and ypmA and the 
difference in the GC content in the ORF of ypmB and ypmA 
from that of the base usage of Y. pseudotuberculosis suggest that 
the ypm gene originates from another organism. The alignment 
of the amino acid sequences of mature proteins of YPMb and 
YPMa revealed that there is 83% homology (108 amino acid 
residues are identical). Between YPMa and YPMb, the central 
region is less homologous than the N- and C-terminal regions. 
Based on the functional similarity of two superantigen molecules, 
the less homology suggested that the central region is less 
important for the function of both YPM molecules. 
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1. Introduction 
Yersinia pseudotuberculosis is a Gram-negative enteropatho-
genic bacillus which is capable to induce not only gastrointes-
tinal symptoms but also a variety of systemic manifestations 
such as fever, scarlatiniform rash and desquamation. Y. pseu-
dotuberculosis is known to elaborate a superantigen Y. pseu-
dotuberculosis-deri\ed mitogen (YPM) [1-6] which plays an 
important role in the pathogenesis of Y. pseudotuberculosis 
infection [7-9]. A superantigen is a highly potent immuno-
stimulatory molecule. Unlike conventional peptide antigen, a 
superantigen binds directly as an intact protein to major his-
tocompatibility complex (MHC) class II molecules on anti-
gen-presenting cells at a site distinct from the antigen-binding 
*Corresponding author. Fax: (81) 3-3411-7308. 
E-mail: tae@nch.go.jp 
1 Present address: National Institute of Cholera and Enteric Diseases, 
P-33, CIT Road, Scheme XM, Beliaghata, P.O. Box 177, 
Calcutta-700 010, India. 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. 
P / /S0014-5793(97)00909-5 
groove. The superantigen/MHC complex then reacts with the 
T-cell receptors (TCR) through the particular fi-chain of var-
iable region (V[3), rather than with the normal antigen-binding 
groove on TCR. The result of these interactions is prolifera-
tion of a large number of T-cells with consequent release of 
cytokines. This ability of the superantigen directly accounts 
for the pathogenic effects and clinical symptoms of the infec-
tion [10,11]. 
In addition to YPM, more than 10 species of bacterial 
superantigens, such as toxic shock syndrome toxin-1, staph-
ylococcal enterotoxins, streptococcal pyrogenic exotoxins, ex-
foliative toxins and streptococcal superantigen, are well estab-
lished [12-14]. Although almost all members are produced by 
Gram-positive cocci, Staphylococcus aureus and Streptococcus 
pyogene, YPM is the only known Gram-negative bacillary 
superantigen whose primary structure substantially differs 
from other bacterial superantigens. 
We investigated a correlation between the presence of ypm 
gene encoding YPM and the production of a superantigen 
among 411 strains of Y. pseudotuberculosis using the colony 
hybridization assay with oligonucleotide probe and the pro-
liferative assay on human peripheral blood mononuclear cells 
(PBMC). Of the 411 strains investigated, 28 strains expressed 
mitogenic activity, despite failure to hybridize with the specific 
probe for the ypm gene [15]. These facts implied that the 
possibility of the production of a novel superantigen by 
j>/wj-negative strains of Y. pseudotuberculosis. This finding 
formed the impetus for the present study in which we report 
the purification, cloning and nucleotide sequencing of a novel 
Gram-negative bacillary superantigen designated as YPM 
type B (YPMb) produced by a >>/wz-negative strain of Y. pseu-
dotuberculosis. (In this nomenclature, the previously reported 
YPM and ypm gene are renamed YPMa and ypmA gene, 
respectively.) 
2. Materials and methods 
2.1. Bacterial strains and culture conditions 
A ypmA-negaXive strain (R-104) of Y. pseudotuberculosis belonging 
to the serotype 0:6, isolated from a wild-mouse in Japan was used in 
the present study, which was kindly donated by Dr. H. Fukushima of 
Public Health Institute of Shimane Prefecture, Matsue, Japan. The 
strain was cultured as described previously [1]. 
2.2. Purification of YPMb 
Cell lysate of Y. pseudotuberculosis R-104, prepared as described 
previously [4], was precipitated with 80% ammonium sulfate. After 
centrifugation at 15 000Xg for 30 min at 4°C, the resulting pellet 
was resuspended in 20 mM Tris-HCl buffer (pH 7.2), and dialyzed 
against the same buffer. Dialyzed sample was purified further by high-
performance ion-exchange chromatography (HPIEC) and reversed-
phase high-performance liquid chromatography (RP-HPLC). The 
used running condition of HPIEC was described previously [4], RP-
HPLC for purification of YPMb was carried out using a Develosil 
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300C4-HG-5 (4.6 X 150 mm) or a Develosil PhA-HG-5 (4.6 X 150 mm) 
previously equilibrated with 30% acetonitrile in 0.1% trifluoroacetic 
acid (TFA) and run with a linear gradient of acetonitrile (30-40% in 
30 min), at a flow rate of 1.0 ml/min. In the entire process of purifi-
cation, the mitogenic activity of a sample was monitored by measur-
ing the proliferative response of human PBMC. 
2.3. Matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) 
Positive-ion MALDI-TOF-MS was performed using a Voyger RP 
time-of-flight mass spectrometer (PerSeptive Biosystems, Inc., Fra-
mingham, MA). The spectrum was obtained using a linear-mode 
measurement. A protein solution (~2 pmol/u.1 in 50% acetonitrile 
in 0.1% TFA) mixed with same volume of matrix solution the super-
natant of 50% acetonitrile solution saturated with 3,5-dimethoxy-4-
hydroxycinnamic acid. An aliquot (1 ul) of the mixture was placed on 
concave surface of a stainless plate. The ions were generated by irra-
diating the sample area with the output of a nitrogen laser (337 nm). 
2.4. Biological assay 
Proliferative response was measured with human PBMC as de-
scribed previously [16]. Vp repertoire specificity was analyzed by a 
semiquantitative PCR method as described previously [1]. 
2.5. Cloning and sequencing of ypmB gene 
The chromosomal DNA from Y. pseudotuberculosis R-104 was par-
tially digested with Sau3Al and then purified by ultracentrifugation in 
10^40% sucrose gradient. DNA fragments with desired size were li-
gated in BamHl site of a vector pUC18. The ligation mixture was 
used to transform Escherichia coli DH-5a. Transformants were trans-
ferred to an Amersham Hybond N + membrane and screened with the 
32P-labelled DNA probe prepared by PCR using the primer pair as 
described previously [7]. Positive colonies were picked up and were 
assayed for mitogenic activity on human PBMC. 
The plasmid DNA from a positive clone was further digested with 
Hindi. The fragment was ligated into the Smal site of pUC18 to 
obtain a subclone. A subclone with the intact ypmB gene, which 
was confirmed by the mitogen assay, was used for sequencing experi-
ments. Nucleotide sequence of the clone was determined by dideoxy-
nucleotide chain termination methods as modified for use with Seque-
nase© (US Biochemical, Cleveland, OH). 
2.6. PCR for the detection of ypmB gene 
PCR for the detection of ypmB gene was performed using the prim-
er pair 5'-TTTCTGTCATTACTGACATTA-3' (sense) and 5'-CCT-
CTTTCCATCCATCTCTTA-3' (anti-sense). The nucleotide sequen-
ces of sense and anti-sense primers are located at positions 13-33 
and 260-280 in ypmB gene, respectively. 
3. Results and discussion 
3.1. Purification of YPMb 
The cell lysate of Y. pseudotuberculosis R-104 was partially 
purified by ammonium sulfate precipitation and HPIEC, as 
described in Section 2.1. The fractions exhibited mitogenic 
activity were pooled and further purified by R P - H P L C with 
a Develosil 300C4-HG-5 column. A peak fraction indicated 
by an arrow in Fig. 1A showed potent mitogenic activity. This 
fraction was subjected to R P - H P L C with Develosil P h A - H G -
5 column to give a pure mitogen and a fraction which showed 
the mitogenic activity was eluted as one of minor peaks (Fig. 
IB). The fraction with marked mitogenicity was subjected to 
rechromatography to give a sharp and single peak as shown in 
Fig. 1C, indicating purification to high homogeneity. 
3.2. Chemical and biological properties of YPMb 
Automated Edman degradation of the purified Y P M b pro-
vided the N-terminal sequence of 39 amino acid residues as 
A - D - Y - D - N - T - L - N - S - I - P - S - L - R - I - P - N - I - E - T - Y - T -
G - X - I - Q - G - K - G - E - V - X - I - R - G - N - K - E - G - K - X - R - (X 
denotes a cycle in which no identifiable residue was detected). 
Out of the determined 39 residues, three amino acid residues 
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Fig. 1. Purification of YPMb. A: RP-HPLC profile of the crude 
YPMb obtained by HPIEC with a TSKgel DEAE-5PW column. 
B: RP-HPLC profile of the mitogenic peak fraction indicated by an 
arrow in (A). An arrow indicates the peak fraction exhibiting potent 
mitogenic activity. C: Rechromatography of the purified preparation 
of YPMb. 
differed between Y P M a and Y P M b . The molecular weight of 
the purified Y P M was measured to be 14629 by M A L D I -
TOF-MS, which is comparable to that of the previously docu-
mented Y P M a (14527). 
Proliferative response of P B M C to the purified Y P M b was 
detected at a concentration as low as 1 pg/ml. The minimum 
176 T. Ramamurthy et al.lFEBS Letters 413 (1997) 174-176 
1 20 
YPMb: MKKKFLSLLT LTFFSGLALA ADYDNTLNSI PSLRIPNIE 
YPMa1 **N*L***** F*L***V*** T********* ********j^ 
40 60 
YPMb: T YTGTIQGKGE VCIRGNKEGK SRGGELYAVL RSTNANA 
YPMa: * ********** ***i****** T********* H***V** 
so 100 
YPMb: DMT LILLCSI-RDG WKEVKRSDID RPLRYEDYYT PGAL 
YPMa: *** ****RNVGGN* *G*I**N*** K**K****** S*-* 
120 140 
YPMb: SWIWEI KNNSSEASDY SLSATVHDDK EDSDVLMKCP 
YPMa: ****** ******T*N* **D******* ******^*** V 
Fig. 2. Comparison of amino acid sequences of precursor proteins 
of YPMb and YPMa. Homologous residues are shown in asterisks. 
A dash indicates a gap of one amino acid residue. 
effective concentration was comparable to that of the known 
YPMa. The purified YPMb was found to stimulate human 
T-cells bearing V(33, 9, 13.1 and 13.2 selectively. This V(3 
repertoire specificity was identical to that of YPMa. 
3.3. Cloning and nucleotide sequence determination of ypmB 
We cloned a gene (ypmB) encoding YPMb and analyzed its 
nucleotide sequence as described in Section 2.5. The nucleo-
tide sequence data obtained in the present study appears in 
the DDBJ, EMBL and GenBank nucleotide sequence data 
bases with the accession number of D88144. The open reading 
frame (ORF) of the ypmB gene (453 bp) encodes a protein 
with 150 amino acid residues, though the precursor protein of 
YPMa consists of 151 amino acid residues. The N-terminal 
39 amino acid residues determined by automated Edman de-
gradation with the purified YPMb completely match the re-
spective amino acid residues deduced from the nucleotide se-
quence. The determined N-terminal sequence of the purified 
protein and the specificity of prokaryote signal peptidase sug-
gest that N-terminal 20 amino acid residues are consisted of a 
signal sequence. Molecular weight of the mature protein of 
YPMb with 130 residues was calculated to be 14596 from the 
nucleotide sequence. This value is nearly identical to the ob-
served mass value (14628) of the purified YPMb measured by 
MALDI-TOF-MS. The alignment of the amino acid sequen-
ces of mature proteins of YPMb and YPMa revealed that 
there is 83% homology (108 amino acid residues are identical) 
(Fig. 2). 
Of the 411 strains of Y. pseudotuberculosis investigated, 
28 strains did not hybridize with the specific probe for the 
ypmA, despite expression of mitogenic activity [15]. It was dem-
onstrated that high possibility of the presence of ypmB in all the 
ypmA-negative and mitogen-positive strains by the PCR test 
using the specific primer pair for ypmB, as described in Section 
2.6. This represents that YPMb is responsible for the rest species 
of superantigen molecule produced by Y. pseudotuberculosis. 
We concluded that YPMb is a variant of YPMa based on 
the similarity in amino acid sequence and the biological prop-
erties. More than 10 species of Gram-positive coccal super-
antigen were known. However, so far, YPMa has been the 
only known Gram-negative bacillary superantigen. In addi-
tion to YPMa, the second Gram-negative bacillary superanti-
gen YPMb has been identified in the present study. 
Between amino acid sequences of YPMa and YPMb, the 
central region is less homologous than the N- and C-terminal 
regions (Fig. 2). As these two superantigen molecules possess 
the same function, the low homology suggests that the central 
region is not important for the function of both YPM mole-
cules. In our previous study, it has been identified through 
competition studies by using synthetic peptides that a region 
of YPMa encompassing amino acid residues 1 through 23 is 
involved in the induction of human PBMC proliferation [16]. 
This is in agreement with the higher homology of the N-ter-
minal portion. 
Analysis of the nucleotide sequence homology between 
ypmB and ypmA showed that there are 88.9%> similarity in 
ORF, 87.6% in upstream of ORF and 52.1% in downstream 
of ORF. Although the GC content of the total DNA from a 
strain of Y. pseudotuberculosis is 46.5% [17], these of the ORF 
of ypmB and ypmA are 34.4% and 35.3%, respectively. The low 
homology in the downstream of ORF and the difference in the 
GC content suggest that the ypm gene originates from other 
organism, implying that the presence of other bacterial super-
antigen produced by other Gram-negative bacillus [18,19]. 
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